The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Steven G. Potkin

Department of Psychiatry

UCI Brain Imaging Center

University of California-Irvine

5251 California Avenue



Name/email consistency: high



  • Department of Psychiatry, UCI Brain Imaging Center, University of California-Irvine, 5251 California Avenue, USA. 2001 - 2011
  • Department of Computer Science, University of California, Irvine, USA. 2003 - 2011


  1. Asenapine: a clinical overview. Potkin, S.G. J. Clin. Psychiatry (2011) [Pubmed]
  2. SNP-based pathway enrichment analysis for genome-wide association studies. Weng, L., Macciardi, F., Subramanian, A., Guffanti, G., Potkin, S.G., Yu, Z., Xie, X. BMC. Bioinformatics (2011) [Pubmed]
  3. Identifying gene regulatory networks in schizophrenia. Potkin, S.G., Macciardi, F., Guffanti, G., Fallon, J.H., Wang, Q., Turner, J.A., Lakatos, A., Miles, M.F., Lander, A., Vawter, M.P., Xie, X. Neuroimage (2010) [Pubmed]
  4. A genome-wide association study of schizophrenia using brain activation as a quantitative phenotype. Potkin, S.G., Turner, J.A., Guffanti, G., Lakatos, A., Fallon, J.H., Nguyen, D.D., Mathalon, D., Ford, J., Lauriello, J., Macciardi, F. Schizophr. Bull (2009) [Pubmed]
  5. Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. Potkin, S.G., Turner, J.A., Fallon, J.A., Lakatos, A., Keator, D.B., Guffanti, G., Macciardi, F. Mol. Psychiatry (2009) [Pubmed]
  6. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Potkin, S.G., Weiden, P.J., Loebel, A.D., Warrington, L.E., Watsky, E.J., Siu, C.O. Int. J. Neuropsychopharmacol. (2009) [Pubmed]
  7. Widespread cortical dysfunction in schizophrenia: the FBIRN imaging consortium. Potkin, S.G., Ford, J.M. Schizophr. Bull (2009) [Pubmed]
  8. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Potkin, S.G., Turner, J.A., Brown, G.G., McCarthy, G., Greve, D.N., Glover, G.H., Manoach, D.S., Belger, A., Diaz, M., Wible, C.G., Ford, J.M., Mathalon, D.H., Gollub, R., Lauriello, J., O'Leary, D., van Erp, T.G., Toga, A.W., Preda, A., Lim, K.O. Schizophr. Bull (2009) [Pubmed]
  9. Genome-wide strategies for discovering genetic influences on cognition and cognitive disorders: methodological considerations. Potkin, S.G., Turner, J.A., Guffanti, G., Lakatos, A., Torri, F., Keator, D.B., Macciardi, F. Cogn. Neuropsychiatry (2009) [Pubmed]
  10. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. Potkin, S.G., Guffanti, G., Lakatos, A., Turner, J.A., Kruggel, F., Fallon, J.H., Saykin, A.J., Orro, A., Lupoli, S., Salvi, E., Weiner, M., Macciardi, F. PLoS. ONE (2009) [Pubmed]
  11. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. Potkin, S.G., Litman, R.E., Torres, R., Wolfgang, C.D. J. Clin. Psychopharmacol (2008) [Pubmed]
  12. New advances in the treatment of schizophrenia. Introduction. Potkin, S.G. J. Clin. Psychopharmacol (2008) [Pubmed]
  13. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. Potkin, S.G., Cohen, M., Panagides, J. J. Clin. Psychiatry (2007) [Pubmed]
  14. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Potkin, S.G., Gharabawi, G.M., Greenspan, A.J., Mahmoud, R., Kosik-Gonzalez, C., Rupnow, M.F., Bossie, C.A., Davidson, M., Burtea, V., Zhu, Y., Trivedi, J.K. Schizophr. Res. (2006) [Pubmed]
  15. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial. Potkin, S.G., Keck, P.E., Segal, S., Ice, K., English, P. J. Clin. Psychopharmacol (2005) [Pubmed]
  16. Psychometric evaluation of the Readiness for Discharge Questionnaire. Potkin, S.G., Gharabawi, G.M., Greenspan, A.J., Rupnow, M.F., Kosik-Gonzalez, C., Remington, G., Ruetsch, C., Revicki, D. Schizophr. Res. (2005) [Pubmed]
  17. Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Potkin, S.G., Anand, R., Alphs, L., Fleming, K. Schizophr. Res. (2003) [Pubmed]
  18. D1 receptor alleles predict PET metabolic correlates of clinical response to clozapine. Potkin, S.G., Basile, V.S., Jin, Y., Masellis, M., Badri, F., Keator, D., Wu, J.C., Alva, G., Carreon, D.T., Bunney, W.E., Fallon, J.H., Kennedy, J.L. Mol. Psychiatry (2003) [Pubmed]
  19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Potkin, S.G., Saha, A.R., Kujawa, M.J., Carson, W.H., Ali, M., Stock, E., Stringfellow, J., Ingenito, G., Marder, S.R. Arch. Gen. Psychiatry (2003) [Pubmed]
  20. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Potkin, S.G., Alva, G., Fleming, K., Anand, R., Keator, D., Carreon, D., Doo, M., Jin, Y., Wu, J.C., Fallon, J.H. Am. J. Psychiatry (2002) [Pubmed]
  21. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. Potkin, S.G., Thyrum, P.T., Alva, G., Bera, R., Yeh, C., Arvanitis, L.A. J. Clin. Psychopharmacol (2002) [Pubmed]
  22. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. Potkin, S.G., Thyrum, P.T., Alva, G., Carreon, D., Yeh, C., Kalali, A., Arvanitis, L.A. J. Clin. Psychopharmacol (2002) [Pubmed]
  23. Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease. Potki, S.G., Anand, R., Hartman, R., Veach, J., Grossberg, G. Prog. Neuropsychopharmacol. Biol. Psychiatry (2002) [Pubmed]
  24. Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. Potkin, S.G., Alva, G., Keator, D., Carreon, D., Fleming, K., Fallon, J.H. Brain Res. (2002) [Pubmed]
  25. Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Potkin, S.G., Thyrum, P.T., Bera, R., Carreon, D., Alva, G., Kalali, A.H., Yeh, C. Clin. Ther (2002) [Pubmed]
  26. The ABC of Alzheimer's disease: ADL and improving day-to-day functioning of patients. Potkin, S.G. Int. Psychogeriatr (2002) [Pubmed]
  27. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Potkin, S.G., Anand, R., Fleming, K., Alva, G., Keator, D., Carreon, D., Messina, J., Wu, J.C., Hartman, R., Fallon, J.H. Int. J. Neuropsychopharmacol. (2001) [Pubmed]
WikiGenes - Universities